InflaRx (IFRX) EPS (Basic) (QoQ) (2017 - 2026)
InflaRx (IFRX) EPS (Basic) (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | InflaRx | 141.98 Mn | -42.27 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -115.74% |
| Dec 31, 2025 | 392.24% |
| Sep 30, 2025 | 12.16% |
| Jun 30, 2025 | -62.28% |
| Mar 31, 2025 | -118.65% |
| Dec 31, 2024 | 344.49% |
| Sep 30, 2024 | -28.53% |
| Jun 30, 2024 | -32.60% |
| Mar 31, 2024 | 20.51% |
| Dec 31, 2023 | -68.77% |
| Sep 30, 2023 | 9.18% |
| Jun 30, 2023 | 100.00% |
| Mar 31, 2023 | -51,228,580.54% |
| Dec 31, 2022 | 390.72% |
| Sep 30, 2022 | -157.27% |
| Jun 30, 2022 | 192.21% |
| Mar 31, 2022 | 100.00% |
| Dec 31, 2021 | -331,844,903.45% |
| Sep 30, 2021 | -179.87% |
| Jun 30, 2021 | 444.90% |